

# ESPRIT

## Efficacy and Safety of PRescribing In Transplantation

February 3rd 2016

██████████  
Project Manager  
National Institute for Health and Care Excellence  
10 Spring Gardens  
London SW1A 2BU

Dear ██████████

**Re: Final Appraisal Determination – Immunosuppressive therapy for kidney transplant in children and adolescents ID 346 (review of technology appraisal guidance 99)**

Thank you for the initial scrutiny letter in relation to the ESPRIT Group's appeal against the above technology appraisal.

You raised two areas for clarification and I am pleased to respond to those now.

*Question 1. Could you confirm that your appeal concerns all of the drugs referred to in FAD 1.4, including everolimus and belatacept? Answer 1. Yes it does.*

*Question 2. I understand your point 2.3 to be an argument that the economic analysis is defective because a key cost of a non-treatment scenario, graft failure and subsequent dialysis or no transplant and continued dialysis has been omitted. That would be a valid point. If I have misunderstood the point please correct me. Answer 2. No, you have not misunderstood.*

We were pleased to hear that there will be an oral appeal hearing and have now received our invitation to that, taking place on March 30<sup>th</sup>.


ESPRIT Directors: **Professor Atholl Johnston**, Clinical Pharmacology, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, **Mr Stephen Pollard**, Consultant Transplant Surgeon, St. James' University Hospital, Leeds. For full list of ESPRIT Group Members see website.

---

ESPRIT Group Secretariat: Tel and Fax: 01483 281321 E-mail: [info@esprit.org.uk](mailto:info@esprit.org.uk) Web: [www.esprit.org.uk](http://www.esprit.org.uk)

The ESPRIT Group is constituted as an independent company limited by guarantee, full name ESPRIT Partnership Ltd., registered in England and Wales no. 06971971. Registered office: 6 Baldwin Crescent, London, SE5 9LQ. Its activities are open to support by educational grants from interested parties. These have included Novartis Pharmaceuticals UK Ltd., Astellas Pharma Ltd, Sandoz and Mylan. However, as an independent group, we do not advocate any particular product and our opinions, recommendations and activities are all our own.

Yours sincerely

  
Professor of Clinical Pharmacology, Barts and the London, Queen Mary's  
School of Medicine and Dentistry

ESPRIT Directors: **Professor Atholl Johnston**, Clinical Pharmacology, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, **Mr Stephen Pollard**, Consultant Transplant Surgeon, St. James' University Hospital, Leeds. For full list of ESPRIT Group Members see website.

---

ESPRIT Group Secretariat: Tel and Fax: 01483 281321 E-mail: [info@esprit.org.uk](mailto:info@esprit.org.uk) Web: [www.esprit.org.uk](http://www.esprit.org.uk)

The ESPRIT Group is constituted as an independent company limited by guarantee, full name ESPRIT Partnership Ltd., registered in England and Wales no. 06971971. Registered office: 6 Baldwin Crescent, London, SE5 9LQ. Its activities are open to support by educational grants from interested parties. These have included Novartis Pharmaceuticals UK Ltd., Astellas Pharma Ltd, Sandoz and Mylan. However, as an independent group, we do not advocate any particular product and our opinions,

recommendations and activities are all our own.